Elutia (ELUT) announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio-including ProxiCor, VasCure and Tyke-following the conclusion of its distribution agreement with LeMaitre Vascular. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELUT:
- Elutia initiates EluPro clinical study to collect real-world outcome data
- Elutia confirms global tariff environment has no material impact on performance
- Elutia announces GPO agreement with Advantus Health Partners
- Elutia publishes new preclinical data in Antibiotics
- Elutia files $100M mixed securities shelf
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue